| name | es-hcm-ugps3-vitamin-d-monitor |
| description | Recommends checking and managing vitamin D according to Endocrine Society guidelines to avoid hypocalcemia in patients receiving bisphosphonates or denosumab for hypercalcemia of malignancy. Use when a clinician notes risk factors for hypocalcemia (e.g., low 25‑OH vitamin D, renal insufficiency) and asks about baseline labs before antiresorptive start. |
Monitor vitamin D levels to prevent hypocalcemia during antiresorptive therapy
STEP 1 — Gather Information
Collect serum 25‑hydroxyvitamin D, corrected serum calcium (or ionized calcium), albumin, estimated glomerular filtration rate (eGFR), serum phosphate and magnesium, and confirm planned antiresorptive agent (IV bisphosphonate or denosumab) for hypercalcemia of malignancy.
STEP 2 — Rule In / Rule Out
Is the 25‑OH vitamin D level <20 ng/mL (deficient) or 20‑29 ng/mL (insufficient) per Endocrine Society cut‑offs? If yes, proceed to repletion; if ≥30 ng/mL (sufficient), vitamin D repletion is not required before antiresorptive therapy.
STEP 3 — Classify or Stratify
Classify vitamin D status: deficient (<20 ng/mL), insufficient (20‑29 ng/mL), sufficient (≥30 ng/mL). Additionally stratify renal function: eGFR <30 mL/min/1.73 m² warrants dose adjustment of bisphosphonate or denosumab and closer calcium monitoring.
STEP 4 — Decide
If deficient: prescribe vitamin D repletion per Endocrine Society guidelines (e.g., 50,000 IU vitamin D3 orally once weekly for 6‑8 weeks, then maintenance 1500‑2000 IU daily). If insufficient: consider empiric supplementation 1500‑2000 IU daily. If sufficient: no routine supplementation; obtain baseline calcium and monitor serum calcium within 24‑48 h after each antiresorptive dose.
Clinical Guardrails / Mimics / Pitfalls
Do not initiate bisphosphonate or denosumab without correcting vitamin D deficiency due to heightened hypocalcemia risk. Avoid interpreting total calcium without albumin correction in hypoalbuminemic patients. Do not give high‑dose vitamin D in the presence of hypercalcemia unless deficiency is confirmed. Monitor for hypocalcemia symptoms (perioral tingling, carpopedal spasm, prolonged QT) and check calcium before each dose in renal impairment. Do not rely solely on vitamin D repletion; continue calcium and renal function surveillance throughout therapy.
Concrete Clinical Example
A 62‑year‑old with lung cancer presents with hypercalcemia of malignancy (serum calcium 13.8 mg/dL, albumin 3.8 g/dL). Planned therapy: zoledronic acid 4 mg IV. Baseline labs show 25‑OH vitamin D 15 ng/mL, eGFR 45 mL/min/1.73 m², phosphate 2.8 mg/dL. Vitamin D deficient → prescribe 50,000 IU vitamin D3 weekly for 8 weeks. After repletion, vitamin D rises to 32 ng/mL, calcium normalizes to 9.2 mg/dL. Administer zoledronic acid, then check serum calcium 24 h post‑dose and weekly for 3 weeks.
Source: Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac621
